Tech Company Financing Transactions
89Bio Funding Round
Longitude Capital Management, OrbiMed and Pontifax Fund participated in a $60 million Series A funding round for 89Bio. The round closed on 10/26/2018.
Transaction Overview
Company Name
Announced On
10/26/2018
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Series A
Investors
Proceeds Purpose
The funding will be used to advance the company's pipeline of biologic and small molecule drug candidates acquired from Teva Pharmaceutical Industries, Ltd.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
535 Mission St. 14th Floor
San Francisco, CA 94105
USA
San Francisco, CA 94105
USA
Phone
Undisclosed
Website
Email Address
Overview
We're a clinical-stage biopharmaceutical company focused on changing the lives of patients living with nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. Our teams in the US and Israel are working to develop highly differentiated medicines that address unmet medical needs based on cutting-edge and robust research.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rohan Palekar
Chief Financial Officer
Ryan Martins
Chief Medical Officer
Hank Mansbach
Chief Operating Officer
Ram Waisbourd
Chief Technical Officer
Quoc Le-Nguyen
Browse more venture capital transactions:
Prev: 10/26/2018: Privy venture capital transaction
Next: 10/26/2018: Tivorsan Pharmaceuticals venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to record every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs